WEX Venture Capital Seeks to Invest up to $100M to Help Advance EV Fleet Transition
WEX (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced that its Board of Directors has authorized a new investment arm of WEX, WEX Venture Capital, to invest up to $100 million through the end of 2025, which will likely be made predominantly in early-stage companies focused on the energy transition, including areas such as fleet electrification, the electric vehicle (EV) charging ecosystem, energy management and optimization, and adjacent technology. WEX Venture Capital has already started to deploy capital, including minority investments in Chargetrip and ev.energy.
“WEX Venture Capital is proof that we do not have to choose between doing what’s right for business and what’s right for the future of mobility,” said Melissa Smith, Chair, Chief Executive Officer, and President, WEX. “From routing and energy management to fuel payment systems, the energy transition will benefit from innovation in fleet management offerings, creating flexibility for our customers to seamlessly charge or fuel at work, home, and en route. WEX Venture Capital’s investments will be aimed at supporting companies focused on the critical back-end infrastructure necessary to achieve widespread commercial EV adoption, while also creating new value for WEX’s global fleet customers navigating the evolving electric mobility ecosystem. This is a crucial moment for WEX and the larger fleet industry, and we’re proud to help lead this transition.”
Already a trusted advisor to fleet mobility customers, including more than 18 million vehicles serviced globally as of Q2 2023, the portfolio companies in which WEX Venture Capital expects to invest will have the potential to benefit from the capital investment as well as the potential commercial opportunities presented by WEX’s fleet mobility customers and partners across the broader and evolving fueling and charging ecosystem.
“In the years to come, the energy transition will transform how we move employees and goods around the economy,” said Jay Dearborn, Chief Strategy Officer, WEX. “WEX Venture Capital positions WEX to not only serve our commercial customers with the innovation we drive from within, but to also participate and help unlock rich innovation that is happening across the ecosystem.”
The new initiative reflects the importance of engaging with outside innovators and companies, which complements WEX’s historical approach to growth through traditional M&A and internal development efforts. WEX Venture Capital diversifies WEX’s long-term strategy by positioning the company to identify new revenue models, provide visibility beyond WEX’s current product roadmap, and participate in the early-stage product innovation ecosystem as many of its fleet mobility customers begin to migrate from internal combustion engine vehicles to EVs and mixed fleets as part of the energy transition.
WEX Venture Capital’s investment thesis is reflected in its recent investments in Chargetrip, a Netherlands-based company focused on range prediction and EV routing for private drivers and commercial fleets, and ev.energy, a UK-based company offering a managed charging software platform for EVs. ev.energy announced its $33 million Series B round of financing today.
“We are thrilled to welcome Chargetrip and ev.energy to the WEX Venture Capital portfolio,” said Carlos Carriedo, Chief Operating Officer, International, WEX. “Chargetrip’s deep expertise in range prediction and routing technology for EV fleets and ev.energy’s managed charging platform are both critical in helping our clients optimize their EV investments. We look forward to collaborating with Chargetrip and ev.energy to help strengthen their first-mover advantage in market awareness, product maturity, and traction as fleets convert to EVs over time.”
“The investment from WEX Venture Capital is a major step towards our goal to be the number one design partner for electrifying fleets. With WEX’s network and fleet software expertise, Chargetrip will be able to access new customers, benefit from WEX leadership’s knowledge, and grow its North American presence,” said Gideon van Dijk, Chief Executive Officer and Co-Founder, Chargetrip.
"WEX Venture Capital is a great partner for ev.energy, giving us access to millions of fleet vehicles across the US and Europe. I'm excited about working with WEX to help fleet managers save thousands and reduce carbon emissions through the vehicle-grid integration of fleet EVs," said Nick Woolley, Chief Executive Officer and Co-Founder, ev.energy.
WEX Venture Capital is launched as the growth of EV adoption reaches an inflection point. Given its leading position in the fuel payments industry, serving over 600,000 fleet customers worldwide, WEX Venture Capital enables WEX to play a meaningful role in the greater electric mobility ecosystem by assisting a variety of new stakeholders, from energy suppliers to charge point operators, OEMs, charging locations, and energy markets, among others as they streamline the future of charging and payments.
For more information about WEX Venture Capital, please visit https://vc.wexinc.com.
About WEX
WEX (NYSE: WEX) is the global commerce platform that simplifies the business of running a business. WEX has created a powerful ecosystem that offers seamlessly embedded, personalized solutions for its customers around the world. Through its rich data and specialized expertise in simplifying benefits, reimagining mobility and paying and getting paid, WEX aims to make it easy for companies to overcome complexity and reach their full potential. For more information, please visit www.wexinc.com .
About WEX Venture Capital
WEX Venture Capital is the venture capital arm of WEX (NYSE: WEX) with an authorization of $100 million in capital focused on identifying and helping advance next-generation technology and companies focused on the energy transition. Investment areas of focus include fleet electrification, the electric vehicle (EV) charging ecosystem, energy management and optimization, and adjacent technology. WEX Venture Capital offers portfolio companies the potential to benefit from the breadth of WEX's global fleet business and expertise, while guiding WEX fleet customers as they navigate the expected global EV transition. For more information, please visit https://vc.wexinc.com.
About Chargetrip
Chargetrip is an API-based SaaS company that enables fleet electrification and e-mobility application development with EV routing and range prediction technology. Its platform routes about 15% of Europe's EV drivers and is trusted by top EV charging, vehicle rental, and energy utility companies globally. In addition to WEX Venture Capital, Chargetrip is backed by world-class investors HSBC Asset Management, Riverstone, Blue Bear Capital, Vindeggen, and Axel Springer Porsche. Learn more at https://chargetrip.com.
About ev.energy
ev.energy is a Certified B Corporation® with a mission to make EV charging greener, cheaper, and smarter for utilities and their customers. Its end-to-end software platform wirelessly connects to a range of electric vehicles and chargers to intelligently manage EV charging while working with utilities to put cash back in customers’ wallets for charging at grid-friendly times. With a global base of utility, vehicle OEM and EVSE partners, ev.energy manages more than 100,000 EVs on its platform each day. Learn more at https://ev.energy/business.
Forward-Looking Statements made by WEX
This press release contains forward-looking statements, including statements regarding expectations for future investments. Any statements that are not statements of historical facts may be deemed to be forward-looking statements. When used in this release, the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seeks,”“will”, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such words. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including: WEX’s ability and timing to execute on any such investments and the success of such investments, as well as other risks and uncertainties identified in Item 1A of WEX’s annual report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on February 28, 2023 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on April 27, 2023 and any subsequent SEC filings. WEX's forward-looking statements do not reflect the potential future impact of any alliance, merger, acquisition, disposition or stock repurchases. The forward-looking statements speak only as of the date of this release and undue reliance should not be placed on these statements. WEX disclaims any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726351925/en/
Contact information
News media:
WEX
Julie Lydon, 415-816-9397
Julie.Lydon@wexinc.com
Investor:
WEX
Steve Elder, 207-523-7769
Steve.Elder@wexinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 15:30:00 EET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activity for ADVC001 in patients with mCRPC (see press release). ADVC001 is a first-in-class 212Pb-PSMA RLT in clinical development, with early data indicating a differentiated and competitive profile both within and beyond its class. Development is advancing rapidly; the Phase 1b therapeutic cohorts were enrolled within ten months, and the commencement of Phase 2 expansion sustains this strong program momentum. The TheraPb Phase 2 expansion will evaluate ADVC001 at two therapeutic dose levels – 160 MB
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 15:00:00 EET | Press release
Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE As creative economies decentralize and new production hubs emerge across EMEA, Luma AI is positioning its capabilities where creative work is increasingly being produced - not just consumed. To build intelligence that truly serves global creators, Luma AI will work alongside them in their markets, cultures, and workflows. London is the first step in that strategy, as it has the unique position as a global center of advertising, brands, and entertainment. “With this Series C raise and the upcoming build-out
Aurigene Oncology Limited Announces Encouraging Initial Data From 1 st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 15:00:00 EET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 14:30:00 EET | Press release
Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after closing the transaction. These include building a dedicated m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
